Real-time trial visibility. Direct sponsor engagement. Patient-PAG matching.
Patient advocacy groups are your most powerful ally. HEKMA helps you find them, join them, and use every tool they offer.
A community of people who truly understand what you're going through.
PAG members get early access to trial opportunities matched by HEKMA AI.
Your aggregated, anonymised data helps PAGs push for better research funding.
Every condition page lists the advocacy groups that support it.
One click to join. No fees, no paperwork, no waiting.
Access trial matching, community, and resources through your PAG.
Patient advocacy groups are powerful yet consistently sidelined by the clinical trial ecosystem.
Patient advocacy groups are routinely excluded from trial launch communications, leaving them unable to inform and prepare their members.
Protocol committees rarely include PAG representatives, resulting in trial designs that don't reflect real patient priorities or lived experience.
Data reaches PAGs months or years after completion, too late to inform patient decisions or advocacy strategy.
Sponsors use PAG networks for recruitment but rarely share insights or revenue with the organizations that made it possible.
Purpose-built tools that give PAGs the visibility, voice, and value they deserve.
Live view of all trials in your disease area, sponsor names, sites, PAG involvement status
Endorse trials you trust. Flag concerns. Your voice on trial listings.
Formally request protocol input. HEKMA routes to sponsor with tracking.
Co-branded referral links tracked back to your PAG
A live view of all trials in your disease area, with full sponsor and PAG involvement data.
| Trial Title | Sponsor | Phase | PAG Involvement | Patient Referrals | Action |
|---|---|---|---|---|---|
| CBD Adjunctive Therapy in Drug-Resistant Epilepsy | GW Pharmaceuticals | Phase III | Advisory Board | 127 | |
| Tirzepatide for Type 2 Diabetes, UAE Cohort | Eli Lilly | Phase III | Participating | 84 | |
| Gene Therapy for Sickle Cell Disease | bluebird bio | Phase II | Invited | 23 | |
| Lecanemab for Early Alzheimer's Disease | Eisai / Biogen | Phase III | None | ||
| Upadacitinib for Rheumatoid Arthritis | AbbVie | Phase IV | Participating | 61 |
Featured patient advocacy organizations on the HEKMA platform.
Join the HEKMA platform and start shaping the future of clinical trials for your community.
